Managed Healthcare Executive October 16, 2024
Logan Lutton, Peter Wehrwein, Managing Editor

Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, highlights the expected shift of Medicare beneficiaries towards Medicare Advantage Prescription Drug (MA-PD) plans.

Due to decreasing Prescription Drug Plan (PDP) options, rising PDP premiums and the additional benefits and risk management capabilities offered by MA-PD plans, there is an expected shift toward MA-PD plans, according to Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy, BluePeak Advisors.

“We’re really not going to see how that membership shifts right until we get through...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, Insurance, Medicare Advantage, Trends
Dr. Oz on Medicare Advantage: 5 things to know
US News names top Medicare Advantage, Part D providers for 2025
Where 6 payers' Medicare Advantage businesses are headed in 2025, per their CEOs
Medicare Advantage Proves To Be the ‘Most Profound’ Disruptor for Nursing Homes, Reshaping Payer Dynamics
Payers ranked by Medicare Advantage market exits | 2025

Share This Article